Who owns enGene Therapeutics Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ENGNW from SEC Form 13F filings across 10 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 10 institutions disclosed 2.5M shares of enGene Therapeutics Inc. worth $709,816 — about 3.5% of shares outstanding; the largest disclosed holder is BVF INC/IL. Source: SEC Form 13F filings, parsed by EvidInvest.
10
13F holders
$709,816
value, 2026 filers
3.5%
of shares outstanding (2.5M sh)
10
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of ENGNW's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BVF INC/ILNEW | 945,402 | $274,072 | 0.0% | 1.4% | new |
| 2 | Blue Owl Capital Holdings LPNEW | 511,177 | $148,190 | 0.0% | 0.7% | new |
| 3 | Caption Management, LLCNEW | 333,675 | $96,732 | 0.0% | 0.5% | new |
| 4 | LMR Partners LLPNEW | 309,763 | $89,800 | 0.0% | 0.4% | new |
| 5 | ARISTEIA CAPITAL, L.L.C.NEW | 197,678 | $47,670 | 0.0% | 0.3% | new |
| 6 | D. E. Shaw & Co., Inc.NEW | 104,622 | $30,330 | 0.0% | 0.2% | new |
| 7 | TORONTO DOMINION BANKNEW | 31,545 | $9,148 | 0.0% | 0% | new |
| 8 | CSS LLC/ILNEW | 16,895 | $4,898 | 0.0% | 0% | new |
| 9 | StoneX Group Inc.NEW | 10,371 | $8,918 | 0.0% | 0% | new |
| 10 | Clear Street Group Inc.NEW | 200 | $58 | 0.0% | 0% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.